97 related articles for article (PubMed ID: 7530468)
1. Economic and clinical evaluation of therapy of HIV-related non-Hodgkin's lymphoma with chemotherapy and granulocyte colony-stimulating factor (G-CSF).
Tirelli U; Vaccher E
Eur J Cancer; 1994; 30A(10):1589-90. PubMed ID: 7530468
[No Abstract] [Full Text] [Related]
2. Effects of recombinant granulocyte colony-stimulating factor (G-CSF) in patients treated with ProMACE-CytaBOM for HIV-related non-Hodgkin's lymphoma (NHL).
Rossi G; Donisi A; Casari S; Re A; Stellini R; Cadeo G; Carosi G
Haematologica; 1998 Apr; 83(4):317-22. PubMed ID: 9592981
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost.
Lee SM; Radford JA; Dobson L; Huq T; Ryder WD; Pettengell R; Morgenstern GR; Scarffe JH; Crowther D
Br J Cancer; 1998 Apr; 77(8):1294-9. PubMed ID: 9579836
[TBL] [Abstract][Full Text] [Related]
4. Addition of granulocyte colony-stimulating factor to chemotherapy in patients with AIDS-related lymphoma: effects on neutrophil Fc gamma receptor expression and soluble Fc gammaRIII plasma levels.
Kersten MJ; de Jong S; Evers LM; Koene HR; van Oers MH
Br J Haematol; 1997 Dec; 99(3):537-41. PubMed ID: 9401062
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients.
Gianni AM; Bregni M; Siena S; Magni M; Di Nicola M; Lombardi F; Tarella C; Pileri A; Bonadonna G
J Clin Oncol; 1992 Dec; 10(12):1955-62. PubMed ID: 1280674
[TBL] [Abstract][Full Text] [Related]
6. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy.
Zagonel V; Babare R; Merola MC; Talamini R; Lazzarini R; Tirelli U; Carbone A; Monfardini S
Ann Oncol; 1994; 5 Suppl 2():127-32. PubMed ID: 7515645
[TBL] [Abstract][Full Text] [Related]
7. Granulocyte colony-stimulating factor (G-CSF) may stimulate HIV-replication during cytostatic chemotherapy.
Weiner SM; Rump JA; Kreise W; Thimme R; Blum HE; Meyerhans A; Schneider J
Eur J Haematol; 1998 Nov; 61(5):354-5. PubMed ID: 9855252
[No Abstract] [Full Text] [Related]
8. Cost-minimization analysis of prophylactic granulocyte colony-stimulating factor after induction chemotherapy in children with non-Hodgkin's lymphoma.
Rubino C; Laplanche A; Patte C; Michon J
J Natl Cancer Inst; 1998 May; 90(10):750-5. PubMed ID: 9605644
[TBL] [Abstract][Full Text] [Related]
9. De-escalation chemotherapy and hematological profiles in patients with advanced Hodgkin's lymphoma.
Seignez A; Casasnovas O; Ferrant E; Bastie JN; Mondoloni P; Aho LS; Boulin M
Int J Clin Pharm; 2015 Dec; 37(6):1033-7. PubMed ID: 26408407
[TBL] [Abstract][Full Text] [Related]
10. G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy.
Vitolo U; Angrili F; DeCosta L; Wetten S; Federico M
Med Oncol; 2016 Dec; 33(12):139. PubMed ID: 27822615
[TBL] [Abstract][Full Text] [Related]
11. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
[TBL] [Abstract][Full Text] [Related]
12. Randomized study of granulocyte colony stimulating factor for childhood B-cell non-Hodgkin lymphoma: a report from the Japanese pediatric leukemia/lymphoma study group B-NHL03 study.
Tsurusawa M; Watanabe T; Gosho M; Mori T; Mitsui T; Sunami S; Kobayashi R; Fukano R; Tanaka F; Fujita N; Inada H; Sekimizu M; Koh K; Kosaka Y; Komada Y; Saito AM; Nakazawa A; Horibe K;
Leuk Lymphoma; 2016 Jul; 57(7):1657-64. PubMed ID: 26694130
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte colony-stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma.
Cortelazzo S; Viero P; Bellavita P; Rossi A; Buelli M; Borleri GM; Marziali S; Bassan R; Comotti B; Rambaldi A
J Clin Oncol; 1995 Apr; 13(4):935-41. PubMed ID: 7535843
[TBL] [Abstract][Full Text] [Related]
14. Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma.
Dranitsaris G; Sutcliffe SB
Leuk Lymphoma; 1995 Mar; 17(1-2):139-45. PubMed ID: 7539658
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142--low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases.
Straus DJ; Huang J; Testa MA; Levine AM; Kaplan LD
J Clin Oncol; 1998 Nov; 16(11):3601-6. PubMed ID: 9817281
[TBL] [Abstract][Full Text] [Related]
16. Cost-benefit analysis of prophylactic granulocyte colony-stimulating factor during CHOP antineoplastic therapy for non-Hodgkin's lymphoma.
Dranitsaris G; Altmayer C; Quirt I
Pharmacoeconomics; 1997 Jun; 11(6):566-77. PubMed ID: 10173030
[TBL] [Abstract][Full Text] [Related]
17. Administration of three cytokines instead of bone marrow transplantation in an HIV+ patient with high-grade lymphoma.
Laporte JP; Lesage S; Woler M; Parlier Y; Daguenel A; Najman A; Gorin NC
Eur J Haematol; 1994 Aug; 53(2):123-5. PubMed ID: 7522189
[No Abstract] [Full Text] [Related]
18. [Effect of granulocyte colony-stimulating factor after chemotherapy with CHOP in patients with non-Hodgkin's lymphoma and HIV infection].
Navarro JT; Ribera JM; Gómez-Espuch J; Feliu E
Med Clin (Barc); 1996 Jun; 107(3):118-9. PubMed ID: 8754503
[No Abstract] [Full Text] [Related]
19. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy.
Molina A; Krishnan AY; Nademanee A; Zabner R; Sniecinski I; Zaia J; Forman SJ
Cancer; 2000 Aug; 89(3):680-9. PubMed ID: 10931469
[TBL] [Abstract][Full Text] [Related]
20. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
